BioSpace News Archive

Across the country, in large urban areas as well as small rural communities, EMTs and paramedics are serving on the frontlines of our nation’s war against the COVID-19 pandemic, oftentimes without the necessary supplies and equipment to ensure the safety of their patients and themselves.

Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of the previously announced public offering, reflective of 7,692,308 shares of its common stock

Infusion therapy involves use of needle or catheter during treatment. This is prescribed to only when patients condition is very serious, that they are not responding to oral medication.

CardioQuipTM, LLC, a medical device manufacturer focused on development and commercialization of patient temperature control and cardiovascular perfusion technology announced today it has received CE Mark approval for the MCH-1000TM Modular Cooler-Heater SeriesTM.

The world’s first whole-body portable ultrasound continues its rapid expansion and distribution around the world while also showing significant clinical utility in fighting the COVID-19 pandemic [26-March-2020] GUILFORD, Conn. , March 26, 2020 /PRNewswire/ -- Butterfly Network, the company helping to transform healthcare with its disruptive, ultrasound-on-chip™ techno

XORTX Therapeutics Inc. is pleased to announce that Dr. Anjay Rastogi has joined the Company’s clinical advisory board. Dr. Allen Davidoff stated, “We are excited that Dr. Anjay Rastogi has agreed to join XORTX’s clinical advisory board. Dr. Rastogi brings substantial

Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang , M.D., Ph.D., President and Chief Executive Officer, plans to present an overview of the company at the upcoming Solebury Trout Virtual Investor Conference. The 25-minute presentation includes an interactive Q&A with participants

Castle Biosciences, Inc., today announced the publication of a multicenter, prospective study demonstrating that DecisionDx ® -UM test results significantly impacted treatment plan recommendations for patients with uveal melanoma (U

SutroVax , a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110 million Series D preferred stock financing, co-led by new investors RA Capital Management and Jan